EVO

Evotec SE Sponsored ADR (EVO) | Rumor.io

Evotec

EVO

Attention (50-day avg)0%

Attention rank (50-day avg)#857

Bullish sentiment (50-day avg)78%

Price to earnings ratio-5.47

Market capitalization565.1M

Earnings per share-0.64

Dividend yield (TTM)54.7%

Revenue (annual)788.4M

Net income (annual)-103.5M

Social

What share of all stock conversation is about EVO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% -0.02

Feb 5

The company reported a 3.7% decrease in net revenue to €514.2 million in Q4 2025, with a 9.5% decrease in total operating revenue to €565.9 million.
The Asia business saw positive q/q growth after a sharp contraction in 3Q, while the Europe business is facing worse headwinds due to regulated markets losing ground to unregulated competitors.
The company's capital allocation strategy is expected to prioritize buybacks over dividends, with a possible flat or growing dividend, according to an investor's analysis.

Generated by AI

Sentiment

Of the messages about EVO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	51.2% -48.8	69.35% -13.16	58.19% -20.51
Bearish	100%	48.8% new	30.65% +13.16	41.81% +20.51

Bullish· Dec 8

The company is making significant advancements in its blockchain technology, including the release of a new tier system and token-gated access for its bot, which is expected to become a major on-chain utility.
The market is rising again, and the company is well-positioned to take advantage of this trend, with a solid week of progress and a clear vision for the future.
The company's focus on transforming raw blockchain data into intelligence is driving innovation and precision, making it an attractive investment opportunity for those looking to capitalize on the growth of the crypto market.

Bearish· Oct 23

$EVO's Q3 earnings report was disappointing, with revenue down 2.4% and EBITA down 18.9%.
The company's management has prioritized growth over margin, leading to a reduction in net headcount and a decrease in profit.
Evolution's Asia business is struggling, with average daily revenues down 10.5% quarter-over-quarter, and the company's management has conceded that its countermeasures will take longer than expected to take effect.

Generated by AI

Topics

Of the messages about EVO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	31.82%
Technical Analysis	—	0%	0%	2.4%
Controversies	—	0%	0%	10.27%
Analysts	—	0%	0%	24.21%
Earnings	—	0%	0%	5.95%
Macro	—	0%	0%	25.35%

Jul 21

Evotec SE adjusts revenue guidance for FY2025 to €760-800M, down from €840-880M, while confirming adjusted EBITDA guidance of €30-50M.
The company anticipates a more profitable revenue mix, which contributed to the adjusted profit guidance.
The market capitalization of Evotec SE is approximately $1.33 billion, with a current price of $3.69 USD.

Generated by AI

Community

Of the messages about EVO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	95.27%	75.94%
Newcomers	0%	0%	4.73%	24.06%

Regulars· Feb 5

Evolution Gaming reported a 3.7% decrease in net revenue to €514.2 million in Q4 2025, with total operating revenues decreasing 9.5% to €565.9 million, and adjusted EBITDA decreasing 6.1%.
Management is guiding for a managed decline, excluding Asia and Europe, which account for three-quarters of $EVO's sales and profits.
The company's capital allocation framework assumes a 60% buyback and 40% dividend payout on 2025 profits, with an EPS impact of +6.2% and a dividend of approximately €2.21 per share.

Newcomers· Jul 17

The Q2 results for Evotec SE ($EVO) have confirmed a shift from a growth darling to a resilient compounding machine, with the company's operational performance meeting expectations despite challenges in Asia and Europe.
The Q2 earnings were fairly in-line with expectations, and the market has re-priced the business as a result, leading to an 8% rally in the stock.
The company's operational performance is strong, with the CEO buying back shares in June, and the company's global expansion is underway, with new partnerships and revenue growth in Asia and the US, but the EBITDA margin has decreased due to expansion costs.

Generated by AI

News

Evotec: The Market Seems Split On The Company's Prospects (NASDAQ:EVO)

Evotec faces deteriorating fundamentals, with 1H26 revenue down nearly 20% and adjusted EBITDA turning sharply negative. Read why EVO stock is a Buy.

9d agoSeeking Alpha

Investment Update: Evotec (NASDAQ:EVO)

Investment Update: Long article based on a reader request.

11d agoSeeking Alpha

Evotec at Morgan Stanley healthcare conference: push to clarify its story

13d agoInvesting.com

Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies

21d agoYahoo Finance

Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors

Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors. The collaboration addresses key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumors by combining Plectonic's programmable LOGIBODY® technology with Evotec's proprietary BiTco platform.

28d agoYahoo Finance

RBC Capital Reaffirms Their Buy Rating on Evotec (0IRF)

Tipranks Press Release.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about EVO also mention

#	Name	Attention
1	ProShares Short SmallCap600SBB	0.01%new
2	PTEC - Global X Funds - Global X PropTech ETF	——
3	Nextdoor Holdings, Inc.KIND	0%new
4	Stifel Financial Corp.SF	0%0
5	Identiv Inc.INVE	0%0
6	FiscalNote Holdings, Inc.NOTE	0%0
7	Goldman Sachs Access U.S. Aggregate Bond ETFGCOR	0%0
8	VanEck Fallen Angel High Yield Bond ETFANGL	0%0
9	iShares Securitized Income Active ETFSECU	0%new
10	CI&T Inc. Class A Common SharesCINT	0%new

Evotec SE Sponsored ADR

Healthcare
Drug Manufacturers - Specialty & Generic

Evotec SE Sponsored ADR is a healthcare and life sciences depositary receipt representing Evotec SE, a drug discovery and development company headquartered in Hamburg, Germany. The company supports pharmaceutical and biotechnology partners with integrated research services across early-stage drug discovery, including target identification, screening, lead optimization, pharmacology, structural biology, and bioanalytics. Its work is organized around discovery and development platforms that help clients advance small molecules and biologics through preclinical research. Evotec SE also operates collaborative research programs and technology-enabled solutions that serve a broad range of therapeutic areas. As a Sponsored ADR, the asset provides U.S. investors with exposure to Evotec SE’s business in a U.S.-traded format while reflecting the company’s role in the global outsourced drug discovery market.

Website

Location

Essener Bogen 7

Hamburg, 22419

Germany

Social

What share of all stock conversation is about EVO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% -0.02

Feb 5

The company reported a 3.7% decrease in net revenue to €514.2 million in Q4 2025, with a 9.5% decrease in total operating revenue to €565.9 million.
The Asia business saw positive q/q growth after a sharp contraction in 3Q, while the Europe business is facing worse headwinds due to regulated markets losing ground to unregulated competitors.
The company's capital allocation strategy is expected to prioritize buybacks over dividends, with a possible flat or growing dividend, according to an investor's analysis.

Generated by AI

Sentiment

Of the messages about EVO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	51.2% -48.8	69.35% -13.16	58.19% -20.51
Bearish	100%	48.8% new	30.65% +13.16	41.81% +20.51

Bullish· Dec 8

The company is making significant advancements in its blockchain technology, including the release of a new tier system and token-gated access for its bot, which is expected to become a major on-chain utility.
The market is rising again, and the company is well-positioned to take advantage of this trend, with a solid week of progress and a clear vision for the future.
The company's focus on transforming raw blockchain data into intelligence is driving innovation and precision, making it an attractive investment opportunity for those looking to capitalize on the growth of the crypto market.

Bearish· Oct 23

$EVO's Q3 earnings report was disappointing, with revenue down 2.4% and EBITA down 18.9%.
The company's management has prioritized growth over margin, leading to a reduction in net headcount and a decrease in profit.
Evolution's Asia business is struggling, with average daily revenues down 10.5% quarter-over-quarter, and the company's management has conceded that its countermeasures will take longer than expected to take effect.

Generated by AI

Topics

Of the messages about EVO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	31.82%
Technical Analysis	—	0%	0%	2.4%
Controversies	—	0%	0%	10.27%
Analysts	—	0%	0%	24.21%
Earnings	—	0%	0%	5.95%
Macro	—	0%	0%	25.35%

Jul 21

Evotec SE adjusts revenue guidance for FY2025 to €760-800M, down from €840-880M, while confirming adjusted EBITDA guidance of €30-50M.
The company anticipates a more profitable revenue mix, which contributed to the adjusted profit guidance.
The market capitalization of Evotec SE is approximately $1.33 billion, with a current price of $3.69 USD.

Generated by AI

Community

Of the messages about EVO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	95.27%	75.94%
Newcomers	0%	0%	4.73%	24.06%

Regulars· Feb 5

Evolution Gaming reported a 3.7% decrease in net revenue to €514.2 million in Q4 2025, with total operating revenues decreasing 9.5% to €565.9 million, and adjusted EBITDA decreasing 6.1%.
Management is guiding for a managed decline, excluding Asia and Europe, which account for three-quarters of $EVO's sales and profits.
The company's capital allocation framework assumes a 60% buyback and 40% dividend payout on 2025 profits, with an EPS impact of +6.2% and a dividend of approximately €2.21 per share.

Newcomers· Jul 17

The Q2 results for Evotec SE ($EVO) have confirmed a shift from a growth darling to a resilient compounding machine, with the company's operational performance meeting expectations despite challenges in Asia and Europe.
The Q2 earnings were fairly in-line with expectations, and the market has re-priced the business as a result, leading to an 8% rally in the stock.
The company's operational performance is strong, with the CEO buying back shares in June, and the company's global expansion is underway, with new partnerships and revenue growth in Asia and the US, but the EBITDA margin has decreased due to expansion costs.

Generated by AI

Evotec

Social

Feb 5

Bullish· Dec 8

Bearish· Oct 23

Jul 21

Regulars· Feb 5

Newcomers· Jul 17

Evotec: The Market Seems Split On The Company's Prospects (NASDAQ:EVO)

Investment Update: Evotec (NASDAQ:EVO)

Evotec at Morgan Stanley healthcare conference: push to clarify its story

Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies

Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors

RBC Capital Reaffirms Their Buy Rating on Evotec (0IRF)

Also Discussed

Evotec SE Sponsored ADR

Company Information

Location

Evotec: The Market Seems Split On The Company's Prospects (NASDAQ:EVO)

Investment Update: Evotec (NASDAQ:EVO)

Evotec at Morgan Stanley healthcare conference: push to clarify its story

Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies

Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors

RBC Capital Reaffirms Their Buy Rating on Evotec (0IRF)

Also Discussed

Social

Feb 5

Bullish· Dec 8

Bearish· Oct 23

Jul 21

Regulars· Feb 5

Newcomers· Jul 17